- Home
- GNFT vs MNPR Comparison
GNFT vs MNPR Comparison
Compare GNFT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- MNPR
- Stock Information
- Founded
- GNFT 1999
- MNPR 2014
- Country
- GNFT France
- MNPR United States
- Employees
- GNFT N/A
- MNPR N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- MNPR Health Care
- Exchange
- GNFT Nasdaq
- MNPR Nasdaq
- Market Cap
- GNFT 186.3M
- MNPR 209.3M
- IPO Year
- GNFT 2019
- MNPR 2019
- Fundamental
- Price
- GNFT $4.14
- MNPR $44.97
- Analyst Decision
- GNFT Strong Buy
- MNPR Strong Buy
- Analyst Count
- GNFT 1
- MNPR 7
- Target Price
- GNFT $13.00
- MNPR $62.00
- AVG Volume (30 Days)
- GNFT 4.0K
- MNPR 69.2K
- Earning Date
- GNFT 09-18-2025
- MNPR 08-08-2025
- Dividend Yield
- GNFT N/A
- MNPR N/A
- EPS Growth
- GNFT N/A
- MNPR N/A
- EPS
- GNFT 0.03
- MNPR N/A
- Revenue
- GNFT $73,187,701.00
- MNPR N/A
- Revenue This Year
- GNFT $15.98
- MNPR N/A
- Revenue Next Year
- GNFT N/A
- MNPR N/A
- P/E Ratio
- GNFT $132.83
- MNPR N/A
- Revenue Growth
- GNFT 105.01
- MNPR N/A
- 52 Week Low
- GNFT $2.55
- MNPR $1.72
- 52 Week High
- GNFT $6.42
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- GNFT 58.36
- MNPR 59.21
- Support Level
- GNFT $3.94
- MNPR $44.26
- Resistance Level
- GNFT $4.20
- MNPR $47.52
- Average True Range (ATR)
- GNFT 0.13
- MNPR 3.49
- MACD
- GNFT 0.05
- MNPR 0.54
- Stochastic Oscillator
- GNFT 91.62
- MNPR 64.49
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.